ClinConnect ClinConnect Logo
Search / Trial NCT06019195

The Effect of Intermittent Fasting on Brain Health

Launched by UNIVERSITY OF OKLAHOMA · Aug 24, 2023

Trial Information

Current as of July 26, 2025

Recruiting

Keywords

Intermittent Fasting Aging

ClinConnect Summary

This clinical trial is studying how a specific eating pattern called intermittent fasting, particularly time-restricted eating (TRE), might benefit brain health as we age. Researchers believe that sticking to a set eating schedule could help improve blood flow in the brain and enhance thinking abilities. They are looking for participants between the ages of 55 and 80 who can hear and see well enough to take part in the study and can read and write in English. To qualify, individuals should also have a certain level of cognitive ability and nutrition status.

If you decide to join this study, you can expect to take part in assessments to measure your brain health and overall well-being. It’s important to note that certain health conditions, such as serious brain diseases or severe mental health issues, may prevent someone from participating. The trial is currently recruiting participants, and everyone is welcome to apply, regardless of gender. This study could help us understand more about how our eating habits might support brain function during aging.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age ≥55 and ≤80 years of age
  • Adequate hearing and visual acuity to participate in the examinations
  • Ability to read and write in English
  • Competence to provide informed consent.
  • Mini Montreal Cognitive Assessment ≥12
  • Mini Nutritional Assessment ≥12
  • Exclusion Criteria:
  • Vision or hearing impairment that would impair the ability to complete study assessments
  • Active CNS disease including multiple sclerosis, uncontrolled seizures, active brain cancer
  • Cerebrovascular accident other than TIA within 60 days prior to Visit 0
  • Major psychiatric disease, including major depression not currently controlled on medications, alcohol or drug abuse
  • Diabetics prescribed sulfonylureas, meglitinides, and insulin
  • Any other medical condition which, in the opinion of investigator, would render the patient inappropriate or too unstable to complete the study protocol

About University Of Oklahoma

The University of Oklahoma, a leading research institution, is dedicated to advancing healthcare through innovative clinical trials and research initiatives. With a robust network of interdisciplinary experts and state-of-the-art facilities, the university fosters an environment that promotes scientific discovery and the development of new treatments. Its commitment to patient-centered research ensures that clinical trials not only adhere to the highest ethical standards but also aim to address pressing health challenges. By collaborating with various stakeholders, including industry partners and healthcare providers, the University of Oklahoma seeks to translate research findings into tangible benefits for communities, ultimately enhancing the quality of care and improving health outcomes.

Locations

Oklahoma City, Oklahoma, United States

Patients applied

0 patients applied

Trial Officials

Andriy Yabluchanskiy, MD, PhD

Principal Investigator

University of Oklahoma

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported